Sengenics to Sell Sequenom's MaterniT21 Test in Malaysia, Singapore | GenomeWeb

NEW YORK (GenomeWeb News) – Sengenics today said that it has entered into an exclusive agreement with the Sequenom Center for Molecular Medicine to launch and promote Sequenom's MaterniT21 Plus prenatal testing service in Malaysia and Singapore.

Sengenics will offer the test, which detects Trisomy 13, 18, and 21, to its partner Ob/Gyn clinicians and hospitals in the two countries. Sengenics is based in Kuala Lumpur and offers genomic-based diagnostic services. It added that it has contracts with eight of the top 10 private hospital chains in the region.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.